{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-003776","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.444671+00:00","generated_at":"2026-06-18T02:17:29.035287+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"HOOKIPA reports Q4 net loss $12.3M, cash $113.4M; HB-200 data expected 2Q2023","bullets":["Cash $113.4M at Dec 31, 2022, plus $15M milestones from Roche & Gilead in early 2023; no SVB exposure.","Q4 revenue $7.8M, full-year $14.2M (down from $18.4M); net loss $64.9M for 2022 vs $75.7M in 2021.","HB-200 Phase 2 data (with pembrolizumab) due 2Q2023; HB-300 trial open; HB-700 IND planned 1H2024.","Roche collaboration: $10M milestone Feb 2023; potential milestones up to $930M plus royalties.","Gilead HBV milestone $5M Jan 2023; HIV program IND expected 2023; HB-101 program discontinued."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-003776","json":"https://secwatch.observer/filing/0001558370-23-003776.json","markdown":"https://secwatch.observer/filing/0001558370-23-003776.md","text":"https://secwatch.observer/filing/0001558370-23-003776.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000155837023003776/0001558370-23-003776-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000155837023003776/hook-20230315x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:17:29.035287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a817e03c4e47dfd2832342f08616c5fcbf6a15a","claim":"HOOKIPA Pharma Inc. reported financial results for Fourth Quarter and Full Year 2022.","evidence_excerpt":"On March 15, 2023, HOOKIPA Pharma Inc. (the “Company”) announced Financial Results for the Fourth Quarter and Full Year 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000155837023003776/0001558370-23-003776-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter and Full Year 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}